Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug;18(4):324-328.
doi: 10.7861/clinmedicine.18-4-324.

Cancer immunotherapy with CAR-T cells - behold the future

Charlotte Graham  1 , Rebecca Hewitson  2 , Antonio Pagliuca, Reuben Benjamin  3
Affiliations

Cancer immunotherapy with CAR-T cells - behold the future

Charlotte Graham et al. Clin Med (Lond). 2018 Aug.

Abstract

Cellular therapy is a key tool to treat haematological malignancies. Over 40,000 allogeneic and autologous haematopoietic stem cell transplants (HSCTs) are performed annually across Europe.1 Since 2017, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells have been licensed outside clinical trials. CAR-T cells have extremely potent antitumour activity, but also have a profile of toxic side effects not seen before. Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects. Patients frequently require admission to intensive care, and management from a number of medical specialties. This exciting and powerful new therapy requires the formation of new multispecialty medical teams for safe delivery and to successfully manage the resultant complications.

Keywords: CAR-T cell related encephalopathy syndrome; CAR-T cells; cancer Immunotherapy; cellular therapy; cytokine release syndrome.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Schematic diagram of CAR-T cells.
Fig 2.
Fig 2.
Organ dysfunction following CAR-T cell therapy.
Fig 3.
Fig 3.
Key teams involved in the delivery of CAR-T cell therapy.
See this image and copyright information in PMC

References

    1. Passweg JR. Baldomero H. Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40,000 transplants annually. Bone Marrow Transplant. 2016;51:786–92. - PMC - PubMed
    1. Blundell J. Researches Physiological and Pathological. London: E. Cox Co. Sons; 1824.
    1. Thomas ED. A history of haemopoietic cell transplantation. Br J Haematol. 1999;105:330–9. - PubMed
    1. Dudley ME. Wunderlich JR. Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–4. - PMC - PubMed
    1. Gross G. Waks T. Eshhar Z. Expression of immunoglobulin T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024–8. - PMC - PubMed

MeSH terms